[PDF] Top 20 Non-Hodgkin's lymphoma: Role of high-dose therapy in diffuse large B-cell lymphoma

... Patients in the high/intermediate (H/I) and high (H) risk groups had superior DFS and overall survival (OS) rates when treated with high-dose consolidation and autologous stem cell trans[r] ... Voir le document complet

... resulting in a double-strand DNA break (DSB). Other effects of doxo- rubicin treatment have been reported, including free radicals release, DNA adducts and formaldehyde-dependent ICL ...Opening of ... Voir le document complet

... Background: Diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL) and follicular lymphoma (FL) are the most common B-cell lymphomas (BCL) ... Voir le document complet

... Introduction Diffuse large B- cell lymphoma (DLBCL) is a common aggressive malignancy of mature B cells, accounting for 30–40% of adult non- Hodgkin’s ... Voir le document complet

... and B- cell non-Hodgkin lymphomas ...Evaluation of the efficacy and safety profiles of different antiviral therapies in HCV patients with B-NHL is ...safety ... Voir le document complet

... enrichment of genes associated with genomic instability and apoptosis in tumor cells of patients within high risk GERS group (supplementary Figure S1 and supplementary Tables S1, S2 and ... Voir le document complet

... concern of modern oncology lies in applying evidence-based medicine to routine medical practice in small scale private centres or community ...hospitals. In 2009, a study among lymphoma ... Voir le document complet

... antigen in patients with diffuse large B-cell lymphoma Diffuse large B-cell lymphoma (DLBCL), representing 40% of ... Voir le document complet

... characteristics of patients from PBL and LNH03 cohorts are provided in Table 1 ...I-II) in 33 (42%) and disseminated (stage IV) in 44 (58%) ...was high in 26 (36%) and ... Voir le document complet

... Introduction B-cell non-Hodgkin lymphoma (NHL) originates from B lymphocytes at various stages of differentiation, from precursor to mature ...with B-cell ... Voir le document complet

... Fallini (Perugia, Italy). The anti-HLA-A ∗ 0201 (BB7.2) used in the CD8 T cell blocking experiments was purchased from BD BioSciences (Oxford, UK). Major histocompatibility complex (MHC) class II expression ... Voir le document complet

... Langerhans cell histiocytosis in association with other lymphoproliferative disorders: a reactive or neoplastic phenomenon? Human Pathology (2006) 37, 32–39 Contact : Claire Geurten / University of ... Voir le document complet

... exception of an increased lactate dehydrogenase (LDH) level (640 U/l; upper limit 429) and a mild renal dysfunction (serum creatinine level 116 ...be lymphoma- and chemotherapy- ...because of the ... Voir le document complet

... splenic B cell lymphomas, the splenic diffuse red pulp lymphoma with villous lymphocytes (SDRPL) has been identified as an entity close to but distinct from SMZL ...1% of B ... Voir le document complet

... L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ... Voir le document complet

... treatment of early stage disease remains a source of ...improvement in disease control with CMT compared with RT alone. 16,17 In contrast, a study from British Columbia reported that ABVD ... Voir le document complet

... number of older DLBCL patients steadily increasing, identifying the treat- ment strategy optimally adapted to this typically fragile population and minimizing unnecessary treatment admin- istration, is an ... Voir le document complet

... potency of RIT against the internalizing antigen CD37 might have been underesti- mated by the use of the radionuclide 131 I, which tends to be cleaved off from the antibody and excreted from the cells upon ... Voir le document complet

... sequences of length 15 bases or longer were subjected to later ...tails in 454 sequencing, the sequences were analyzed semi-manually, distinguishing the false ‘A’ signals in the ...set of ... Voir le document complet

... outcome of low-risk patients treated for localized DLBCL can be improved by the addition of only four doses of rituximab to ...proportion of our patients might have been cured with this latter ... Voir le document complet